Visiteur non identifié - Connexion - Inscrivez-vous
Medis Technologies Ltd. (NASDAQ:MDTL) announced today that it has
received a special permit (SP -14504) from the U.S. Department of
Transportation which authorizes aircraft passengers and crew members
to carry up to three 24/7 Power Pack micro fuel cell devices for
personal use aboard aircraft on one's person or in carry-on baggage
without being subject to the Hazardous Materials Regulations (HMR).
The outer casing of each Medis 24/7 Power Pack micro fuel cell device
must be legibly and durably marked with the following: "DOT SP-14504
APPROVED FOR CARRIAGE IN AIRCRAFT" and the fuel cell must be of the
same design as tested and passed the UL2265C certification
requirements and the IEC PAS 62282-6-1 Safety Criteria for Micro Fuel
Cell Power Systems.
"We are pleased to receive this special permit from the Department
of Transportation allowing passengers and crew members to carry our
24/7 Power Packs on passenger carrying aircraft," said Robert K.
Lifton, Chairman & CEO of Medis Technologies Ltd. "Our Medis
scientists have worked diligently to make sure that our Power Pack
meets the most stringent safety regulations. We are proud to be the
developer and producer of the first fuel cell to be allowed on
passenger carrying aircraft by the DOT as well as the first consumer
fuel cell to be listed by the Underwriters' Laboratories (UL) and that
our fully automated line in Ireland has successfully passed initial
production inspection by the UL. We pledge our continued commitment to
the safety of our fuel cell products while at the same time, they
continue to be green to the benefit of the environment."
Medis Technologies' primary focus is on its fuel cell technology.
Its business strategy is to sell its products to end users through
branded OEM partnerships, retail outlets, service providers and to the
military and other markets. Medis' wholly-owned subsidiary, Cell
Kinetics Ltd., is engaged in the development and commercialization of
the CKChip, a unique cell carrier platform intended for simultaneous
fluoroscopic monitoring and analysis of thousands of individual living
cells over time.
This press release may contain forward-looking statements, which
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. In some cases you can
identify those so-called "forward looking statements" by words such as
"may," "will," "should," "expects," plans," "targets," "believes,"
"anticipates," "estimates," "predicts," "potential," or "continue" or
the negative of those words and other comparable words. These forward
looking statements are subject to risks and uncertainties, product
tests, commercialization risks, availability of financing and results
of financing efforts that could cause actual results to differ
materially from historical results or those anticipated. Further
information regarding these and other risks is described from time to
time in the Company's filings with the SEC. We assume no obligation to
update or alter our forward-looking statements made in this release or
in any periodic report filed by us under the Securities Exchange Act
of 1934 or any other document, whether as a result of new information,
future events or otherwise, except as otherwise required by applicable
federal securities laws.
This press release is available on Medis' web site at
www.medistechnologies.com.
Sélectionnez votre lecteur de news préféré ci-dessous :
Ou bien intégrez le flux XML dans votre agrégateur RSS par défaut : 
